Sona Engages Clinical Trial Clinic for First-in-Human Early Feasibility Study of its THT Cancer Therapy
First Patients Expected to be Enrolled This Month
Halifax, Nova Scotia – (Newsfile Corp. – June 16, 2025) – Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company”, “Sona”) an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, today announced that it has entered into a clinical trial agreement for an early feasibility study clinical trial of its Targeted Hyperthermia Therapy (“THT”). Sona has engaged Bradford Hill Investigacion Clinica (“Bradford Hill”) in Santiago, Chile for a study of Sona’s THT treatment for up to ten patients with advanced melanoma.
